Compare Stocks: PHAR, GMTX, NAMS, and PGEN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GMTX Gemini Therapeutics	$64.51 +1.4%	$75.17	$1.16 ▼ $14.10	$2.80B	-0.12	189,291 shs	684,730 shs
NAMS NewAmsterdam Pharma	$23.20 -4.0%	$25.56	$21.02 ▼ $42.21	$2.77B	0.1	1.91 million shs	1.55 million shs
PGEN Precigen	$8.54 +4.0%	$7.06	$2.99 ▼ $8.98	$3.04B	0.92	4.75 million shs	6.36 million shs
PHAR Pharming Group	$9.75 -2.0%	$11.15	$9.62 ▼ $21.34	$690.09M	-0.05	36,233 shs	12,208 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GMTX Gemini Therapeutics	+1.41%	-1.12%	-19.41%	-15.41%	-2.38%
NAMS NewAmsterdam Pharma	0.00%	+2.75%	-10.25%	-33.39%	-20.98%
PGEN Precigen	0.00%	+10.19%	+19.61%	+51.42%	+155.69%
PHAR Pharming Group	0.00%	-6.79%	-14.92%	-29.19%	-36.65%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GMTX Gemini Therapeutics	$64.51 +1.4%	$75.17	$1.16 ▼ $14.10	$2.80B	-0.12	189,291 shs	684,730 shs
NAMS NewAmsterdam Pharma	$23.20 -4.0%	$25.56	$21.02 ▼ $42.21	$2.77B	0.1	1.91 million shs	1.55 million shs
PGEN Precigen	$8.54 +4.0%	$7.06	$2.99 ▼ $8.98	$3.04B	0.92	4.75 million shs	6.36 million shs
PHAR Pharming Group	$9.75 -2.0%	$11.15	$9.62 ▼ $21.34	$690.09M	-0.05	36,233 shs	12,208 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GMTX Gemini Therapeutics	+1.41%	-1.12%	-19.41%	-15.41%	-2.38%
NAMS NewAmsterdam Pharma	0.00%	+2.75%	-10.25%	-33.39%	-20.98%
PGEN Precigen	0.00%	+10.19%	+19.61%	+51.42%	+155.69%
PHAR Pharming Group	0.00%	-6.79%	-14.92%	-29.19%	-36.65%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GMTX Gemini Therapeutics	0.00	N/A	N/A	N/A
NAMS NewAmsterdam Pharma	2.85	Moderate Buy	$49.73	114.34% Upside
PGEN Precigen	2.83	Moderate Buy	$13.67	60.03% Upside
PHAR Pharming Group	2.20	Hold	$38.67	296.58% Upside

Current Analyst Ratings Breakdown

Latest PHAR, GMTX, NAMS, and PGEN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/25/2026	PGEN Precigen	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$12.00
9/24/2026	PGEN Precigen	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$12.00
9/23/2026	PHAR Pharming Group	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$38.00
9/22/2026	PHAR Pharming Group	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$37.00
9/14/2026	PHAR Pharming Group	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$37.00
9/8/2026	NAMS NewAmsterdam Pharma	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$52.00
8/7/2026	PHAR Pharming Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D)
8/6/2026	NAMS NewAmsterdam Pharma	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$51.00 ➝ $50.00
8/5/2026	PGEN Precigen	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$14.00 ➝ $18.00
8/5/2026	PGEN Precigen	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/3/2026	PGEN Precigen	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$14.00

(Data available from 10/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	$2.89 per share	N/A
NAMS NewAmsterdam Pharma	$22.50M	123.26	N/A	N/A	$5.97 per share	3.89
PGEN Precigen	$9.68M	314.52	N/A	N/A	$0.06 per share	142.33
PHAR Pharming Group	$376.13M	1.83	$0.20 per share	48.62	$3.95 per share	2.47

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GMTX Gemini Therapeutics	-$71.87M	-$1.00	N/A	N/A	N/A	N/A	-38.78%	-35.88%	N/A
NAMS NewAmsterdam Pharma	-$203.82M	-$2.16	N/A	N/A	N/A	-3,644.21%	-34.81%	-31.50%	11/4/2026 (Estimated)
PGEN Precigen	-$250.64M	-$1.04	N/A	11.70	N/A	-183.98%	423.75%	84.39%	11/12/2026 (Estimated)
PHAR Pharming Group	$2.85M	$0.12	81.25	36.11	N/A	2.51%	3.40%	1.90%	11/5/2026 (Estimated)

Latest PHAR, GMTX, NAMS, and PGEN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2026	Q2 2026	NAMS NewAmsterdam Pharma	-$0.4819	-$0.52	-$0.0381	-$0.52	$2.83 million	$3.70 million
8/4/2026	Q2 2026	PGEN Precigen	-$0.0121	$0.05	+$0.0621	$0.05	$27.98 million	$54.98 million
7/30/2026	Q2 2026	PHAR Pharming Group	$0.0630	$0.02	-$0.0430	$0.02	$99.52 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	N/A
NAMS NewAmsterdam Pharma	N/A	N/A	N/A	N/A	N/A
PGEN Precigen	N/A	N/A	N/A	N/A	N/A
PHAR Pharming Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GMTX Gemini Therapeutics	N/A	71.49	71.49
NAMS NewAmsterdam Pharma	N/A	9.03	9.03
PGEN Precigen	2.15	4.58	3.89
PHAR Pharming Group	0.34	3.01	2.31

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GMTX Gemini Therapeutics	75.42%
NAMS NewAmsterdam Pharma	89.89%
PGEN Precigen	33.51%
PHAR Pharming Group	0.03%

Insider Ownership

Company	Insider Ownership
GMTX Gemini Therapeutics	12.90%
NAMS NewAmsterdam Pharma	12.74%
PGEN Precigen	41.40%
PHAR Pharming Group	2.07%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GMTX Gemini Therapeutics	30	43.33 million	37.74 million	Not Optionable
NAMS NewAmsterdam Pharma	100	119.54 million	104.31 million	Optionable
PGEN Precigen	47	356.51 million	208.92 million	Optionable
PHAR Pharming Group	407	70.78 million	69.31 million	Not Optionable

PHAR, GMTX, NAMS, and PGEN Headlines

Recent News About These Companies

HC Wainwright Raises Earnings Estimates for Pharming Group

October 2 at 7:26 AM | marketbeat.com

Grifols (NASDAQ:GRFS) & Pharming Group (NASDAQ:PHAR) Head to Head Contrast

October 2 at 4:15 AM | americanbankingnews.com

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Receives Average Rating of "Hold" from Brokerages

October 2 at 4:15 AM | americanbankingnews.com

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Stock Rated "Hold" by Wall Street Analysts

October 2 at 4:13 AM | marketbeat.com

Q3 EPS Estimates for Pharming Group Boosted by HC Wainwright

October 1 at 6:12 AM | americanbankingnews.com

Analysts Issue Forecasts for Pharming Group Q3 Earnings

October 1 at 6:11 AM | marketbeat.com

Pharming: Chief Executive Officer Fabrice Chouraqui Steps Down with Immediate Effect

September 30, 2026 | ideal-investisseur.frI

Pharming Appoints Leverne Marsh, Kenneth Lynard as Co-CEOs

September 29, 2026 | finance.yahoo.com

Pharmaceutical Executive Daily: Fabrice Chouraqui Steps Down as CEO of Pharming

September 29, 2026 | pharmexec.comP

Pharming Group (NASDAQ:PHAR) Shares Gap Down - Here's What Happened

September 29, 2026 | marketbeat.com

Pharming Group N.V.: Pharming announces CEO transition

September 29, 2026 | finanznachrichten.de

Pharming CEO Fabrice Chouraqui Steps Down, Names Leverne Marsh, Kenneth Lynard Interim Co-CEOs

September 29, 2026 | rttnews.com

Pharming CEO Fabrice Chouraqui Resigns After Disagreement on Direction

September 29, 2026 | marketwatch.com

Pharming announces CEO transition

September 29, 2026 | globenewswire.com

FDA Accepts Pharming's SNDA For Lower-Dose Joenja In Children With APDS

September 26, 2026 | rttnews.com

Pharming Group N.V. Announces U.S. FDA Acceptance And Priority Review Of sNDA For Lower Doses Of Joenja To Treat Children With APDS

September 25, 2026 | marketscreener.comM

Pharming Group (NASDAQ:PHAR) Sees Large Volume Increase - Time to Buy?

September 25, 2026 | marketbeat.com

Pharming Says FDA Accepts sNDA for Lower-Dose Joenja in Children With APDS

September 25, 2026 | marketscreener.comM

Pharming announces U.S. FDA acceptance and Priority Review of sNDA for lower doses of Joenja® to treat children with APDS

September 25, 2026 | globenewswire.com

Pharming Group's (PHAR) Buy Rating Reaffirmed at HC Wainwright

September 22, 2026 | marketbeat.com

Pharming Group N.V. Announces Positive Phase II Topline Data For Leniolisib In PIDs With Immune Dysregulation Accepted As Late-Breaking Abstract At ESID 2026

September 22, 2026 | marketscreener.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

PHAR, GMTX, NAMS, and PGEN Company Descriptions

Gemini Therapeutics NASDAQ:GMTX

$64.51 +0.90 (+1.41%)

As of 10/2/2026

Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

NewAmsterdam Pharma NASDAQ:NAMS

$23.20 -0.96 (-3.97%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$23.72 +0.53 (+2.26%)

As of 10/2/2026 07:59 PM Eastern

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Precigen NASDAQ:PGEN

$8.54 +0.33 (+4.02%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$8.55 +0.01 (+0.12%)

As of 10/2/2026 07:50 PM Eastern

Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

Pharming Group NASDAQ:PHAR

$9.75 -0.20 (-2.01%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$9.90 +0.15 (+1.58%)

As of 10/2/2026 07:30 PM Eastern

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PHAR, GMTX, NAMS, and PGEN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PHAR, GMTX, NAMS, and PGEN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PHAR, GMTX, NAMS, and PGEN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

PHAR, GMTX, NAMS, and PGEN Company Descriptions

Gemini Therapeutics NASDAQ:GMTX

NewAmsterdam Pharma NASDAQ:NAMS

Precigen NASDAQ:PGEN

Pharming Group NASDAQ:PHAR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PHAR, GMTX, NAMS, and PGEN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PHAR, GMTX, NAMS, and PGEN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PHAR, GMTX, NAMS, and PGEN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

PHAR, GMTX, NAMS, and PGEN Company Descriptions

Gemini Therapeutics NASDAQ:GMTX

NewAmsterdam Pharma NASDAQ:NAMS

Precigen NASDAQ:PGEN

Pharming Group NASDAQ:PHAR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools